Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization

Table 2 Univariate analysis of survivors vs non-survivors at 3 mo after transarterial chemoembolization

Parameters	Survivors, n = 125	Non-survivors, n = 56	P value
Age in yr	52.56 ± 9.966	51.27 ± 9.212	0.18
Sex, men/women	114/11	45/11	0.04
Cause of liver disease, hepatitis B/C/B and C/others	113/1/0/11	50/2/1/3	0.157
Tumor size, < 5 cm/≥ 5 cm, < 10 cm/≥ 10 cm	29/57/39	10/29/17	0.659
Number of tumors, 1/2/≥ 3	62/10/53	20/2/34	0.06
Liver cirrhosis, no/yes	36/89	12/44	0.299
Ascites, no/small/moderate-massive	68/47/10	23/23/10	0.087
CTPV, no/yes	110/15	48/8	0.67
Invade left and right liver lobes, no/yes	85/40	34/22	0.34
Type of gross pathology, massive / nodular and diffuse	78/47	34/22	0.829
PVTT type, I/II/III/IV	24/52/44/5	5/25/24/2	0.354
Inferior vena cava tumor thrombus, no/yes	119/6	52/4	0.775
Arteriovenous fistula, no/yes	89/36	36/20	0.352
Total bilirubin, µmol/L	15 (11.15-21.75)	22.25 (17.175-32)	< 0.01
Prealbumin, mg/L	119 (87-159.5)	91.5 (67.25-120.5)	< 0.01
Albumin, g/L	36.407 ± 4.749	37.205 ± 4.853	0.758
Hemoglobin, g/L	127 (115-142)	127 (113.25-143)	0.89
WBC, 109/L	5.06 (4.06-6.27)	5.09 (3.61-6.72)	0.87
PLT, 109/L	119.00 (86.00-180.50)	111.00 (69.25-178.25)	0.15
INR	1.11 (1.06-1.19)	1.12 (1.05-1.26)	0.33
PT, S	14.20 (13.70-15.20)	14.35 (13.70-15.78)	0.38
APTT, S	39.60 (37.25-42.80)	39.35 (36.32-42.85)	0.47
ALT, U/L	41.00 (29.50-62.00)	58.00 (41.25-85.75)	< 0.01
AST, U/L	56.00 (41.00-81.00)	109.00 (72.00-161.75)	< 0.01
GGT, U/L	188.00 (109.00-300.50)	256.00 (186.00-415.25)	< 0.01
Cholinesterase, kU/L	4.88 (3.44-5.84)	3.89 (2.69-5.4675)	0.02
Creatinine, µmol/L	68.60 (58.20-77.25)	66.95 (54.98-79.60)	0.63
AFP, µg/L	1210 (47.86-1210)	1210 (270-1210)	0.34
Child-Pugh grade, A/B/C	94/30/1	29/25/2	< 0.01
ECOG score, 0/1/2/3	8/102/14/1	0/40/15/1	0.016
ALBI grade, 1/2/3	43/79/9	13/41/2	0.31
MELD score	7.53 (5.88-9.02)	9.10 (7.08-11.19)	< 0.01

AFP: Alpha fetoprotein; ALBI: Albumin-bilirubin; ALT: Alanine aminotransferase; APTT: Activated partial thromboplastin time; AST: Aspartate aminotransferase; CTPV: Cavernous transformation of the portal vein; ECOG: Eastern Cooperative Oncology Group; GGT: Gamma-glutamyl transpeptidase; INR: International normalized ratio; MELD: Model of end-stage liver disease; PLT: Platelets; PVTT: Portal vein tumor thrombosis; WBC: White blood cell.